



NeuroScientific
BIOPHARMACEUTICALS

Level 1, 45 Stirling Highway
Nedlands WA 6009 Australia
www.neuroscientific.com

GLAUCOMA STUDY UPDATE

Perth, Australia; 3 February 2020: NeuroScientific Biopharmaceuticals Ltd (ASX:NSB, “NSB” or the “Company”), would like to advise that the Lion’s Eye Institute is continuing in their work to process the samples from the glaucoma animal study. This pivotal preclinical study, involving NSB’s lead drug candidate EmtinB, is being run by researchers at the Lions Eye Institute and involves a pig model of raised intra-ocular pressure induced glaucoma.

The dosing stage of the study was completed on ten pigs at the end of 2019. Lions Eye institute are now processing the large volume of samples obtained during the study and are aiming to report the full results in this quarter. Professor Dao-Yi Yu, Head of Pharmacology Department at the Lion’s Eye Institute, commented, “The study is progressing well, and I look forward to providing results to NSB in the near future”.

Success in this study will allow the Company to progress into testing EmtinB in glaucoma patients in clinical trials this year. Glaucoma is one of the leading causes of blindness in the world and EmtinB has the potential to be a leading disease modifying treatment for this disease.

NSB’s CEO & Managing Director, Matt Liddelow stated, “We are pleased with the work that Lion’s Eye Institute has done so far on the study and we look forward to providing a comprehensive update upon release of the results”.

Additionally, the preclinical safety and toxicity studies for EmtinB are progressing as expected with the highest dose level of 300mg/kg being well tolerated and no abnormal findings reported to date.

NSB is also pleased to announce that Abby Macnish has been appointed as co-Company Secretary, effective immediately.

About NeuroScientific Biopharmaceuticals Ltd

NSB (ASX:NSB) is a drug development company focused on developing peptide-based pharmaceutical drugs for the treatment of neurodegenerative conditions with high unmet medical need. The Company’s product portfolio includes EmtinB, a novel therapeutic peptide most advanced as a treatment for Alzheimer’s disease; and other related peptides (EmtinAc, EmtinAn, and EmtinBn) which have demonstrated similar therapeutic potential as EmtinB. For more information, please visit www.neuroscientific.com

Contacts

Matthew Liddelow
CEO and Managing Director
ml@neuroscientific.com
+61 8 6382 1805

Brian Leedman
Chairman
bl@neuroscientific.com
+61 412 281 780